scholarly journals Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma

Blood ◽  
2016 ◽  
Vol 127 (25) ◽  
pp. 3127-3132 ◽  
Author(s):  
Mark Roschewski ◽  
Louis M. Staudt ◽  
Wyndham H. Wilson
Keyword(s):  
Clonal Evolution ◽  
Response Assessment ◽  
Circulating Tumor Dna ◽  
Dynamic Monitoring ◽  
Liquid Biopsies ◽  
Real Time Analysis ◽  
Non Hodgkin Lymphoma ◽  
Tumor Dna ◽  
Generation Sequencing ◽  
Level Monitoring

Abstract Response assessment in lymphoma relies on imaging scans that do not capture biologic processes at the molecular level. Monitoring circulating tumor DNA (ctDNA) with next-generation sequencing–based assays can detect recurrent disease prior to scans and “liquid biopsies” for somatic mutations address tumor heterogeneity, clonal evolution, and mechanisms of resistance to guide precision treatment. Preanalytic collection and processing procedures should be validated and standardized. We describe emerging applications of ctDNA monitoring including real-time analysis of tumor dynamics, preclinical disease detection, and precision-directed treatment paradigms.

scholarly journals Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers

2020 ◽  
pp. 192-201 ◽  
Author(s):  
Peter Vu ◽  
Yulian Khagi ◽  
Paul Riviere ◽  
Aaron Goodman ◽  
Razelle Kurzrock
Keyword(s):  
Independent Predictor ◽  
Survival Curve ◽  
Tumor Biology ◽  
Circulating Tumor Dna ◽  
Liquid Biopsies ◽  
Metastatic Solid Tumor ◽  
Aggressive Tumor ◽  
The Relationship ◽  
Tumor Dna ◽  
Generation Sequencing

PURPOSE Studies have demonstrated an association between quantity of circulating tumor DNA (ctDNA) and poorer survival. We investigated the relationship between percent ctDNA (%ctDNA), total number of ctDNA alterations, and overall survival (OS) in liquid biopsies. MATERIALS AND METHODS Overall, 418 patients with blood-based next-generation sequencing (54 to 73 genes) were analyzed. Eligible patients included those who had advanced/metastatic solid tumor malignancies and never received immunotherapy treatment, which may alter the survival curve in patients with high mutational burden. RESULTS Patients with a high (≥ 5%) %ctDNA had significantly shorter OS versus those with intermediate (≥ 0.4% to < 5%) or low (< 0.4%) values (median OS, 7.0 v 14.1 v not reached [NR] months, respectively; P < .0001). Patients with a high (≥ 5) total number of alterations had significantly shorter OS versus those with intermediate (≥ 1.46 to < 5), low (< 1.46), or no alterations (median OS, 4.6 v 11.7 v 21.3 v NR months, respectively; P < .0001). The total number of alterations correlated with %ctDNA (r = 0.85; 95% CI, 0.81 to 0.87; P < .0001). However, only an intermediate to high total number of alterations (≥ 1.46) was an independent predictor of worse OS (hazard ratio, 1.96; 95% CI, 1.30 to 2.96; P = .0014; multivariate analysis). CONCLUSION We demonstrate that the total number of alterations and %ctDNA have prognostic value and correlate with one another, but only the total number of alterations was independently associated with survival outcomes. Our findings suggest that the total number of alterations in plasma may be an indicator of more aggressive tumor biology and therefore poorer survival.

scholarly journals Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Liwei Lv ◽  
Yuanbo Liu
Keyword(s):  
Hodgkin Lymphoma ◽  
B Lymphocytes ◽  
Therapeutic Response ◽  
Circulating Tumor Dna ◽  
Clinical Applications ◽  
Common Type ◽  
Liquid Biopsies ◽  
Non Hodgkin Lymphoma ◽  
Treatment Prognosis ◽  
Tumor Dna

Non-Hodgkin lymphoma (NHL) is a common type of hematological malignant tumor, composed of multiple subtypes that originate from B lymphocytes, T lymphocytes, and natural killer cells. A diagnosis of NHL depends on the results of a pathology examination, which requires an invasive tissue biopsy. However, due to their invasive nature, tissue biopsies have many limitations in clinical applications, especially in terms of evaluating the therapeutic response and monitoring tumor progression. To overcome these limitations of traditional tissue biopsies, a technique known as “liquid biopsies” (LBs) was proposed. LBs refer to noninvasive examinations that can provide biological tumor data for analysis. Many studies have shown that LBs can be broadly applied to the diagnosis, treatment, prognosis, and monitoring of NHL. This article will briefly review various LB methods that aim to improve NHL management, including the evaluation of cell-free DNA/circulating tumor DNA, microRNA, and tumor-derived exosomes extracted from peripheral blood in NHL.

Sign in / Sign up

Export Citation Format

Share Document